U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...

Hume Body Pod 2026 Consumer Report: What Hume Health Discloses About 8-Electrode BIA Technology, 45 Body Composition Metrics, and At-Home Body Analysis

An informational overview examining category context, publicly available product disclosures, and what consumers often ...